Novo Nordisk applies for US and European approval of sickle cell disease treatment etavobivat
NVO Novo Nordisk ADR
$40.65 -1.07%
View chart & analysis → - 1Novo Nordisk has submitted a new drug application for etavobivat for adolescents aged 12 and older and adults to the US FDA and a marketing authorization application to the European EMA.
- 2Based on the Phase 3 HIBISCUS results announced in April 2026, etavobivat showed a 27% reduction in the annual rate of vaso-occlusive crises (VOCs) compared to placebo.
- 3Based on the Phase 3 HIBISCUS results announced in April 2026, etavobivat showed a delay of approximately 4 months in the occurrence of the first vaso-occlusive crisis (VOC) compared to placebo.
So what's the key point?
Novo Nordisk has applied for permission to sell a new medicine that treats sickle cell disease in the US and Europe. This medicine was confirmed to reduce the occurrence of vaso-occlusive crises by 27%.
Source Stocktwits +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.